Schiff Acted as Underwriters’ Counsel in GT Biopharma’s $23.7M Nasdaq Up-Listing Offering
Schiff Hardin LLP advised Dawson James Securities, Inc. as underwriter in GT Biopharma, Inc.’s Nasdaq up-listing offering of 4.3 million units.
Schiff Hardin LLP advised Dawson James Securities, Inc. as underwriter in GT Biopharma, Inc.’s Nasdaq up-listing offering of 4.3 million units. Gross proceeds from the offering are approximately $23.7 million. GT Biopharma is a clinical stage biopharmaceutical company focused on the development and commercialization of immunology therapeutic products based on its proprietary trispecific killer engagers (TriKE™) target-directed natural killer cell engager platform. The offering closed on Feb. 17, 2021.
Smart In Your World
Your goals define our mission. Whether an immediate need or a long-term objective, ArentFox Schiff helps you reach your full potential. As industry insiders, we partner with you to develop practical business strategies and sophisticated legal solutions to achieve today’s targets and anticipate tomorrow’s problems. We get you across the finish line.
Contacts
-
Contact:
Nathan Carlile, Head of Firmwide Communications
- Related Industries
- Related Practices